[{"indications": "Indications\u00a0\n(From Protein kinase inhibitors: British National Formulary)\nPazopanib, a tyrosine kinase inhibitor, is licensed for advanced renal cell carcinoma, as first-line treatment and for patients who have had previous treatment with cytokine therapy for advanced disease.", "name": "PAZOPANIB", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.1 Cytotoxic drugs", "8.1.5 Other antineoplastic drugs", "Protein kinase inhibitors"], "cautions": "Cautions\u00a0see section 8.1; monitor liver function\r\nbefore treatment and at least monthly for the first 4 months\u2014consult\r\nproduct literature; control blood pressure\r\nbefore initiating and monitor blood pressure\r\nthroughout treatment (consider dose reduction or interruption if hypertension\r\nuncontrolled despite anti-hypertensive therapy); susceptibility to QT-interval prolongation (including electrolyte\r\ndisturbances, concomitant use of drugs that prolong QT-interval); patients at risk of myocardial\r\ninfarction, ischaemic stroke or\r\ntransient ischaemic attack, cardiac disease; increased\r\nrisk of haemorrhage; increased risk of\r\ngastro-intestinal perforation or fistulas; discontinue treatment 7 days before elective surgery and restart\r\nonly if adequate wound healing; monitor\r\nthyroid function; monitor for proteinuria; interactions: Appendix 1 (pazopanib)", "side-effects": "Side-effects\u00a0see section 8.1; also\r\nabdominal pain, dyspepsia, diarrhoea, weight loss, anorexia, taste\r\ndisturbance, flatulence, hepatic dysfunction, hyperbilirubinaemia,\r\nhypertension, flushing, chest pain, oedema, epistaxis, voice changes,\r\nheadache, dizziness, malaise, paraesthesia, hypothyroidism, proteinuria\r\n(discontinue if grade 4), blood disorders (including thrombocytopenia),\r\nmuscle spasm, myalgia, sweating, skin reactions, dry skin, hair and\r\nskin discoloration; less commonly hepatic failure,\r\ngastro-intestinal perforation, peritonitis, pancreatitis, fistula,\r\ncardiac dysfunction, transient ischaemic attack, stroke, myocardial\r\ninfarction, myocardial ischaemia, bradycardia, haemorrhage, hypertensive\r\ncrisis, QT-interval prolongation, pulmonary embolism, peripheral neuropathy,\r\nmenstrual disturbances", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/208714.htm", "doses": ["adult over 18 years, 800\u00a0mg\r\nonce daily; adjust dose in steps of 200\u00a0mg according to tolerability\r\n(max. 800\u00a0mg daily)"], "pregnancy": "Pregnancy\u00a0avoid unless potential benefit outweighs risk\u2014toxicity in animal studies; effective contraception\r\nadvised during treatment; see also Pregnancy and Reproductive\r\nFunction"}]